Table 2.

Pathologic findings in FAT1-associated MN

Patient Number	Number of Glomeruli	Number of Sclerosed Glomeruli	Interstitial Fibrosis and Tubular Atrophy (%)	IF Microscopy	TBM Deposits	EM Stage
1	17	2	20	IgG 3+, C3 1+, IgG4 3+	No	I
2	17	6	20	IgG 3+, C3 1+	Yes	II
3	43	18	60	IgG 3+, C3 1+, IgG4 3+	Yes	II
4	86	68	80	IgG 3+, C3 1+	Yes	II
5	36	4	20	IgG 3+	No	II
6	6	1	20	IgG 3+, C3 1+	No	II
7	57	2	5	IgG 3+, C3 1+, IgG4 3+, IgG2 2+	No	II
8	50	9	5	IgG 2+, C3 1+	No	II
9	55	2	10	IgG 2+, IgG4 2+	No	II
10	41	2	10	IgG 3+, C3 1+, IgG4 3+	No	II
11	18	1	10	IgG 2+, C3 1+, IgG4 3+	No	II
12	16	0	10	IgG 2+	No	I
13	7	0	20	IgG 1–2+, C3 1+	No	I
14	16	4	20	IgG 3+, C3 1+	No	I

Mayo Clinic cohort patients 1–5 and 11–14; Cedars Sinai cohort patients 6–10. EM, electron microscopy.